Adjuvant Moderately Hypofractionated Intensity-modulated Radiotherapy for Cervical Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-75
SponsorManni Huang
About this trial
To investigate the safety and efficacy of moderately hypofractionated intensity-modulated radiotherapy in the treatment of postoperative cervical cancer
Eligibility criteria
Qualifiers
ECOG performance status 0 or 1;
Histologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma;
Status post radical hysterectomy with pelvic lymph node dissection with or without para-aortic lymph node dissection, and postoperative radiotherapy initiated within 3 months;
For squamous cell carcinoma: meeting Sedlis criteria; for adenocarcinoma and adenosquamous carcinoma: meeting the "four-factor model";
Disqualifiers
History of active malignant tumor within 3 years prior to initial treatment（except for the cervical cancer）and any locally curable tumors treated with radical therapy;
Any high-risk factor confirmed by postoperative pathology: positive lymph node metastasis, positive parametrial invasion, or positive resection margin;
History of neoadjuvant therapy prior to enrollment;
Local recurrence or distant metastasis prior to enrollment;
Trial design
Treatments tested in this trial
- Postoperative Radiotherapy
Treatment groups
154 Participants
are divided into 1 treatment groupSponsors and collaborators
Manni Huang
Lead sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Sponsor institution
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Collaborator
Source ClinicalTrials.gov